INTELLIA THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

24 10月 2024 09:46:04 条件 NetDania Notify

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

24 10月 2024 08:01:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 10月 2024 09:45:05 条件 NetDania Notify

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

10 10月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

07 10月 2024 07:30:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 10月 2024 10:23:57 条件 NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 10月 2024 16:01:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

03 10月 2024 09:45:08 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 10月 2024 09:45:32 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

01 10月 2024 13:25:49 条件 NetDania Notify

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

01 10月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12 9月 2024 07:30:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

11 9月 2024 10:45:32 条件 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 9月 2024 10:37:45 条件 NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 9月 2024 16:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

08 8月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

01 8月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

30 7月 2024 07:30:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

24 7月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Intellia Therapeutics Announces CFO Transition

26 6月 2024 07:30:00 条件 Nasdaq GlobeNewswire